UA85359C2 - Таблетка, содержащая гранулированный материал с kmd-3213 - Google Patents

Таблетка, содержащая гранулированный материал с kmd-3213

Info

Publication number
UA85359C2
UA85359C2 UAA200809667A UAA200809667A UA85359C2 UA 85359 C2 UA85359 C2 UA 85359C2 UA A200809667 A UAA200809667 A UA A200809667A UA A200809667 A UAA200809667 A UA A200809667A UA 85359 C2 UA85359 C2 UA 85359C2
Authority
UA
Ukraine
Prior art keywords
kmd
pharmaceutically acceptable
tablet containing
granulated material
containing granulated
Prior art date
Application number
UAA200809667A
Other languages
English (en)
Ukrainian (uk)
Inventor
Цуйоси Наганума
Мицуо Мурамацу
Original Assignee
Киссеи Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32588229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85359(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Киссеи Фармасьютикал Ко., Лтд. filed Critical Киссеи Фармасьютикал Ко., Лтд.
Publication of UA85359C2 publication Critical patent/UA85359C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA200809667A 2002-12-16 2003-12-11 Таблетка, содержащая гранулированный материал с kmd-3213 UA85359C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002364238 2002-12-16

Publications (1)

Publication Number Publication Date
UA85359C2 true UA85359C2 (ru) 2009-01-12

Family

ID=32588229

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200507046A UA84694C2 (ru) 2002-12-16 2003-12-11 Капсула для лечения дизурии, содержащая гранулиновое индолиновое соединение - блокатор -адренорецепторов
UAA200809667A UA85359C2 (ru) 2002-12-16 2003-12-11 Таблетка, содержащая гранулированный материал с kmd-3213

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA200507046A UA84694C2 (ru) 2002-12-16 2003-12-11 Капсула для лечения дизурии, содержащая гранулиновое индолиновое соединение - блокатор -адренорецепторов

Country Status (23)

Country Link
US (2) US20060018959A1 (ru)
EP (2) EP2402010A1 (ru)
JP (1) JP4633469B2 (ru)
KR (2) KR101072909B1 (ru)
CN (2) CN101069685B (ru)
AU (1) AU2003289320C1 (ru)
BR (1) BR0317349A (ru)
CA (1) CA2507002C (ru)
EA (1) EA008196B1 (ru)
ES (1) ES2544560T3 (ru)
HR (1) HRP20050544B1 (ru)
IL (1) IL169040A (ru)
IS (1) IS7929A (ru)
ME (2) MEP10808A (ru)
MX (1) MXPA05006513A (ru)
NO (1) NO20053467L (ru)
NZ (1) NZ540664A (ru)
PL (1) PL220457B1 (ru)
RS (1) RS58025B1 (ru)
TW (2) TWI382838B (ru)
UA (2) UA84694C2 (ru)
WO (1) WO2004054574A1 (ru)
ZA (1) ZA200504613B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557758C (en) 2004-03-05 2013-09-10 Kissei Pharmaceutical Co., Ltd. Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
JPWO2006038611A1 (ja) * 2004-10-05 2008-05-15 キッセイ薬品工業株式会社 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
WO2008114800A2 (en) * 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
WO2012000926A1 (de) 2010-06-28 2012-01-05 Ratiopharm Gmbh Silodosin-cyclodextrin einschlussverbindungen
WO2012010669A2 (de) 2010-07-23 2012-01-26 Ratiopharm Gmbh Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
EP2474529B1 (en) 2010-12-23 2014-05-14 Sandoz AG Crystalline forms of an active pharmaceutical ingredient
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP6031722B2 (ja) * 2011-08-31 2016-11-24 国立大学法人 千葉大学 女性の排尿障害の治療剤
MX2014009889A (es) * 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9115085B2 (en) 2012-07-16 2015-08-25 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
JP6392207B2 (ja) 2013-03-26 2018-09-19 キッセイ薬品工業株式会社 シロドシンの苦味をマスキングした経口投与製剤
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
KR102206104B1 (ko) 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN103933001A (zh) * 2014-05-09 2014-07-23 浙江华海药业股份有限公司 一种稳定的赛洛多辛口服固体药物组合物及其制备方法
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN108685867A (zh) * 2017-04-06 2018-10-23 昆明积大制药股份有限公司 一种赛洛多辛薄膜衣片及其制备方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
CN111437260A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 用于制备盐酸美金刚固态药物组合物的方法
JP7262005B2 (ja) * 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法
CN114601826B (zh) * 2022-03-31 2024-06-04 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060073A (en) 1963-03-02 1967-02-22 Benger Lab Ltd 2,2,2-trichlorethyl hydrogen succinate and salts
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
DE69319551T2 (de) * 1992-12-02 1998-10-29 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
EP0758244B2 (en) 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
JP4014068B2 (ja) * 1999-07-28 2007-11-28 芦森工業株式会社 エアバッグ装置
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
AU2001256714A1 (en) * 2000-05-15 2001-11-26 Kissei Pharmaceutical Co. Ltd. Water-based liquid preparation
RS20100015A (sr) * 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
JP2001288115A (ja) 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
WO2002069957A1 (en) * 2001-03-01 2002-09-12 Grelan Pharmaceutical Co., Ltd. Fenofibrate-containing composition
US6786714B2 (en) * 2001-04-12 2004-09-07 James W. Haskew Delivery system for liquid catalysts
GB0113843D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same

Also Published As

Publication number Publication date
AU2003289320B2 (en) 2008-08-21
NZ540664A (en) 2007-09-28
KR20100133024A (ko) 2010-12-20
MXPA05006513A (es) 2005-09-08
KR20050084316A (ko) 2005-08-26
JP4633469B2 (ja) 2011-02-16
HK1085131A1 (en) 2006-08-18
IL169040A (en) 2013-04-30
NO20053467L (no) 2005-07-15
TW200944200A (en) 2009-11-01
WO2004054574A1 (ja) 2004-07-01
US20120064154A1 (en) 2012-03-15
PL377495A1 (pl) 2006-02-06
CN100339078C (zh) 2007-09-26
TWI382838B (zh) 2013-01-21
UA84694C2 (ru) 2008-11-25
BR0317349A (pt) 2005-11-16
CN1726028A (zh) 2006-01-25
KR101077061B1 (ko) 2011-10-26
MEP10808A (en) 2010-06-10
CN101069685A (zh) 2007-11-14
PL220457B1 (pl) 2015-10-30
US20060018959A1 (en) 2006-01-26
CN101069685B (zh) 2011-12-14
AU2003289320A1 (en) 2004-07-09
AU2003289320C1 (en) 2018-09-06
TW200418457A (en) 2004-10-01
RS58025B1 (sr) 2019-02-28
EP1574215A1 (en) 2005-09-14
ZA200504613B (en) 2006-08-30
TWI325318B (en) 2010-06-01
EP1574215B1 (en) 2015-07-15
HRP20050544A2 (en) 2006-09-30
HRP20050544B1 (hr) 2017-12-01
KR101072909B1 (ko) 2011-10-17
EA200500985A1 (ru) 2005-12-29
ME00076B (me) 2011-02-10
HK1107768A1 (en) 2008-04-18
EP1574215A4 (en) 2009-07-01
IS7929A (is) 2005-07-01
EP2402010A1 (en) 2012-01-04
RS20050470A (sr) 2007-09-21
ES2544560T3 (es) 2015-09-01
EA008196B1 (ru) 2007-04-27
CA2507002A1 (en) 2004-07-01
JPWO2004054574A1 (ja) 2006-04-20
CA2507002C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
US10328028B2 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
IL101162A0 (en) Pharmaceutical compositions for oral administration comprising an indole derivative
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
SE9901573D0 (sv) New compounds
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
NO20051709L (no) Kystallforbindelse for fast oralt medikament samt fast oralt medikament omfattende denne til behandling av dysuria
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
TW200503775A (en) Pharmaceutical composition and method for treating
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
RU2003100507A (ru) Фармацевтические композиции
JPWO2004066998A1 (ja) 安定な経口用固形医薬組成物
UA86782C2 (ru) Применение галоидного производного гидроксамовой кислоты в лечении нейродегенеративных заболеваний центральной нервной системы
JP2020125330A (ja) 縮合アミノジヒドロチアジン誘導体の医薬組成物
EA202193065A1 (ru) Фармацевтическая композиция, содержащая акситиниб
SE9901572D0 (sv) New compounds
TW200517127A (en) Novel composition
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
TR200103473T2 (tr) Kristalli azabisiklo (2.2.2) oktan-3-amin sitratin polimorfları ve farmasötik kompozisyonları.